Supporting Information

Copper(II) Mixed-Ligand Polypyridyl Complexes with

Doxycycline - Structures and Biological Evaluation

Olufunso O. Abosede, Nilima A. Vyas, Sushma B. Singh, Avinash S. Kumbhar, Anup Kate,

Anupa A. Kumbhar, Ayesha Khan, Andrea Erxleben, Peter Smith, Carmen de Kock, Frank

Hoffmann, Joshua A. Obaleye

Table of Content	Page			
Scheme S1. Synthetic route of 1-4	2			
Figure S1. Packing diagram of 2	3			
Figure S2. Intermolecular and intramolecular hydrogen bonding in 2	3			
Figure S3. Absorption spectra of 1-4 in water	4			
Figure S4. ESI-MS spectra of 1-4	5-10			
Figure S5-S7. DNA cleavage study by 1-4	11-12			
Synthesis. binary complex [Cu(Hdoxycycline) ₂](NO ₃) ₂	12			
Table 1. Antimalarial activity of complexes against CQ-sensitive <i>P. falciparum</i> NF54 strain				
Table 2. Antimalarial activity of complexes against CQ-resistant P. falciparum Dd2 strain	13			
Figure S8-S10. Study of stability of complexes in water, DMSO and 0.1M NaCl solution				
Figure S11. EPR spectra of complex 1-4 in frozen DMSO				

Scheme S-1: Synthetic route of complexes 1-4



2



Figure S1: Packing Diagram of complex 2



Figure S2: Intermolecular and intramolecular hydrogen bonding in 2



Figure S3: UV-Vis. Spectra of complex (1-4) a) 20 µM b) 1 mM in water at room temperature













Figure S4.ESI-MS of A) 1, B) 2, 2b C) 3, 3b, D) 4 in methanol

(a) 2 3 5 6 78 Lane No. 1 4 NC (form II) SC (form I) % nc 7.3 13.6 16.1 9.2 13.215.8 15.8 % sc 92.7 86.4 65.7 90.8 86.8 84.2 84.2 (b) Lane No. 8 1 2 3 5 6 7 NC (form II) SC (form I) 8.7 % nc 32.4 40.9 54.0 68.5 77.8 100 100 % sc 91.3 67.6 59.1 46.0 31.5 22.2 -------(c)



Figure S5: Photographs of 1% Agarose gel showing cleavage of plasmid *pBR*322 DNA by **1-3** incubated at 37°C for 20 min. [DNA] = 300 ng. (a) **1**; Lane 1, DNA Control; Lanes 2-7, DNA + 10, 20, 30, 40, 50, 100 μ M (b) **2**; Lane 1, DNA Control; Lanes 2-7, DNA + 5, 10, 20, 30, 40, 50,100 μ M (c) **3**; Lanes 1-5, DNA + 10, 20, 30, 40, 50 μ M; Lane 6, DNA Control.



Figure S6: 1% agarose gel showing the effect of inhibitors on cleavage of *pBR*322 plasmid DNA by **2** on incubation for 20 min at 37°C. [DNA] = 300 ng, [**2**] =30 μ M. Lane 1 DNA control; lane 2, DNA + [**2**]; lane 3, DNA + **2** + DMSO; lane 4, DNA + **2** + mannitol (50 mM); lane 5, DNA + **2** + DABCO (10 mM); lane 6, DNA + **2** + NaN₃ (20 mM); lane 7, DNA + **2** +SOD (15 units).



Figure S7: 1% agarose gel showing the effect of inhibitors on cleavage of *pBR*322 plasmid DNA by **3** on incubation for 20 min at 37°C. [DNA] = 300 ng, [**3**] = 30 μ M; Lane 1, DNA + **3** + DMSO; lane 2, DNA + **3** + mannitol (50 mM); lane 3, DNA + **3** + DABCO (10 mM); lane 4, DNA + **3** + NaN₃ (20 mM) lane 5, DNA + **3** + SOD (15 units); lane6 DNA + **3**; lane 7, DNA control

Synthesis of binary complex [Cu(Hdoxycycline)₂](NO₃)₂.0.121 g (0.5 mM) CuNO₃.3H₂O and 0.513 g (1 mM) doxycycline hyclate were stirred at room temperature in 10 ml methanol for five hr. The resulting green solution was allowed to evaporate slowly at room temperature. Green crystalline solid formed after one week was filtered and washed with water and dried in vacuum desiccator over calcium chloride. Yield: 0.3525 g, 74%; FT-IR (KBR pellet, v cm⁻¹): 3431, 3390, 3292, 30.55, 2879, 2845, 2708, 1610, 1570, 1454, 1381, 1325, 1244, 1215, 1170, 1128, 1060, 1039 1001, 935, 864, 711, 661, 584, 511, 466 ESI-MS (*m/z* positive mode): [M-(2NO₃)+H)]⁺, 950.2; [M-NO₃]⁺, 1014.1 and [M-(NO₃)+Na]⁺, 1036.1.

Compound	IC ₅₀	Relative	Relative
	(µM)	activity to	activity to
		doxycycline ^a	$CQDP^{b}$
1	12.11	1.61	0.004
2	2.00	9.75	0.026
3	0.35	55.71	0.15
4	1.10	17.72	0.047
$[\operatorname{Cu}(\operatorname{dox})_2]^{2+d}$	20.46	0.95	0.003
Doxycycline hyclate	19.50	-	0.003
Chloroquine Diphosphate(CQDP)	0.052	375.00	-

Table 1: Antimalarial activity of complexes against CQ-sensitive P. falciparum NF54 strain

^{*a*} Relative activity = IC_{50} of doxycycline/ IC_{50} of complex, ^{*b*} Relative activity = IC_{50} of CQDP/ IC_{50} of complex, ^{*c*} dox= doxycycline

Table 2: Antimalarial activity of complexes against CQ-resistant *P. falciparum* Dd2 strain

Compound	IC ₅₀ (µM)	Relative activity to doxycycline ^a	Relative activity to CQDP ^b	Resistance Index ^c
1	4.86	2.23	23.17	0.40
2	0.85	12.7	132.51	0.42
3	0.62	17.53	181.66	1.78
4	0.59	18.42	190.90	0.54
$[Cu(dox)_2]^{2+d}$	6.41	1.70	17.57	0.31
Doxycycline hyclate	10.87	-	10.36	0.56
Chloroquine Diphosphate(CQDP)	112.63	0.10	-	2165.96
Artesunate	9.23	1.17	12.20	-

^a Relative activity = IC_{50} of doxycycline/ IC_{50} of complex, ^b Relative activity = IC_{50} of CQDP/ IC_{50} of complex, ^c Resistance Index= IC_{50} towards Dd2/ IC_{50} towards NF54, ^d dox= doxycycline.





Figure S8: Absorption spectra of a)1, b) 2, c)3 and d) 4 in DMSO at 0 h, after 5 and 24 h, room temperature





Figure S9: Absorption spectra of a)1, b) 2, c)3 and d) 4 in water at 0 h, after 5 and 24 h, room temperature





Figure S10: Absorption spectra of a)1, b) 2, c)3 and d) 4 in 1mM NaCl Solution at 0 h, after 5 and 24 h, room temperature



SCAN RANGE







Figure S11: EPR spectra of complex 1 a), 2 b),3 c), 4 d) in frozen DMSO